Jose Fernando Moura, PhD路 @FernandoOnco 路 X路路 2 days agoScore70
Body
The RASolute 302 brought the standing ovation. 馃憦
Now the SCLC community is hoping DeLLphi-305 will bring the same emotion to #ESMO26.
Different tumors. Same hope. More time for our patients. 馃
#DeLLphi305 #SCLC #LCSM @Amgen @BalazsHalmosMD @StephenVLiu @myESMO
146 views 路 2 likes 路 0 reposts 路 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Jose Fernando Moura, PhD 路 x.com